Publication:
Midazolam for the treatment of phantom limb pain exacerbation: Preliminary reports

dc.contributor.authorC. Vichitranandaen_US
dc.contributor.authorS. Pausawasdien_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-09-07T09:47:51Z
dc.date.available2018-09-07T09:47:51Z
dc.date.issued2001-06-21en_US
dc.description.abstractPhantom pain is one of the most difficult intractable pains to manage. The pain may result from the imbalance of self-sustaining neural activity that exceeds the inhibitory control. The management of acute severe exacerbation of phantom pain is extremely difficult. Midazolam acts by potentiation of gamma aminobutyric acid (GABA) and enhance the inhibitory action of glycine receptor at spinal neurons. We describe two preliminary reports of complete pain relief of severe phantom pain exacerbation by intravenous midazolam 3-5 mg.en_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.84, No.2 (2001), 299-302en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-0035006629en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/26756
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035006629&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleMidazolam for the treatment of phantom limb pain exacerbation: Preliminary reportsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0035006629&origin=inwarden_US

Files

Collections